L.V. Ivanitskiy - Reumatologist, Moscow Regional Research Clinical Institute named after M.F.Vladimirskiy E-mail: l.iwanitskiy@gmail.com E.V. Smirnova - Post-graduate Student, Faculty of Fundamental Medicine, Department of Internal Medicine, Lomonosov Moscow State University E-mail: elena.smirnova881@gmail.com T.N. Krasnova - Ph.D. (Med.), Associate Professor, Faculty of Fundamental Medicine, Department of Internal Medicine, Lomonosov Moscow State University E-mail: krasnovamgu@yandex.ru L.M. Samokhodskaya - Ph.D. (Med.), Associate Professor, Medical Scientific Educational Centre of Lomonosov Moscow State University E-mail: slm@fbm.msu.ru

Systemic lupus erythematosus (SLE) is an autoimmune systemic disease characterized by the autoantibodies formation and development of immune inflammation affecting many organs and systems. The clinical symptoms, different prognosis and course of the disease probably are related to the predominant pathogenic type of disturbances. Pathogenesis of systemic lesions in SLE has several major areas - cytotoxic, immunologic and thrombotic with the subsequent development of inflammatory reactions. Genetic disorders in the pathogenesis of SLE are discussed for decades. According to the GWAS reports in different populations there are revealed different candidate genes associated with autoimmunity disorders. Great importance among genetic factors in the development of SLE genes belongs to molecules of histocompatibility complex class II and III (MHC II and III), Fc receptors, cytokines and disturbances of neutrophil function. These studies are discussed in the article suggest that the development and clinical variability SLE are largely associated with genetic disorders. Individual assessment of gene polymorphic variants will allow a personalized approach to the management and treatment of patients with SLE and choose the most appropriate therapy based on the predisposition to a particular clinical course of the disease.

 

1. Tareeva I.E., SHilov E.M., Krasnova T.N. i dr. Volchanochnyjj nefrit v seredine KHKH veka i v nachale KHKHI veka // Terapevticheskijj arkhiv. 2001. № 6. S. 5-10.
2. Nobee A., Vaillant A.J., Akpaka P., et al. Systemic lupus Erythematosus (SLE): a 360 degree review // American Journal of Clinical Medical Medicine Research. 2015. V. 3. № 4. R. 60-63.
3. Cameron J.S. Lupus nephritis // Journal of American Society of Nephrology. 1999. № 10. R. 413-424.
4. Yuan Y.J., Luo X.B., Shen N. Current advances in lupus genetic and genomic studies in Asia // Lupus. 2010. V. 19. № 12. R. 1374-1383.
5. Yang J., Yang W, Hirankarn N. et al. Elf1 is associated with systemic lupus erythematosus in asian populations // Human Molecular Genetics. 2011. № 20. R. 601-607.
6. Fernando M.M., Stevens C.R., Sabeti P.C., et al. Identification of twoindependent risk factors for lupus within the MHC in United Kingdom families // Plos Genetics. 2007. № 3. R. e192.
7. Truedsson L., Bengtsson A.A., Sturfelt G. Complement deficiencies andsystemic lupus erythematosus // Autoimmunity. 2007. № 40. R. 560-566.
8. Fan Y., Tao J.H., Zhang L.P. et al. Association of blk(rs13277113, rs2248932) polymorphism with systemic lupus erythematosus: ameta-analysis // Molecular Biology Reports. 2010. V. 38. № 7. R. 4445-4453.
9. Aitman J., Dong R., Vyse T.J. et al. Copy number polymorphism in fcgr3 predisposes to glomerulonephritis in rats and humans // Nature. 2006. V. 439. № 7078. R. 851-855.
10. Fanciulli P.J., Norsworthy E., Petretto, et al. Fcgr3b copy number variation isassociated with susceptibility to systemic, but not organ-specific, autoimmunity // Nature Genetics. 2007. V. 39. № 6. R. 721-723.
11. Molokhia M., Fanciulli M., Petretto E.  et al. Fcgr3b copy number variation isassociated with systemic lupus erythematosus risk in afro-caribbeans // Rheumatology. 2011. V. 50. № 7. R. 1206-1210.
12. Morris D.L., Roberts A.L., Witherden A.S. et al. Evidence for both copynumber and allelic (NA1/NA2) risk at the fcgr3b locus in systemic lupuserythematosus // European Journal of Human Genetics. 2010. V. 18. № 9. R. 1027-1031.
13. Bouts Y.M, Wolthuis D.F., Dirkx M.F. et al. Apoptosis and NET formation in thepathogenesis of SLE // Autoimmunity. 2012. № 45. R. 597-601.
14. Donnelly S., Roake W., Brown S. et al. Impaired recognition of apoptoticneutrophils by the C1q/calreticulin and CD91 pathway in systemic lupuserythematosus // Arthritis & Rheumatology. 2006. № 54. R. 1543-1556.
15. Pieterse E, van der Vlag J. Breaking immunological tolerance in systemiclupus erythematosus // Frontiers in Immunology. 2014. № 5. R. 164.
16. Kaplan M.J. Neutrophils in the pathogenesis and manifestations of SLE // Nature Reviews Rheumatology. 2011. № 7. R. 691-699.
17. Hacbarth E., Kajdacsy-Balla A. Low density neutrophils in patients with systemic lupus erythematosus, rheumatoid arthritis, and acute rheumaticfever // Arthritis & Rheumatology. 1986. № 29. R. 1334-1342.
18. Villanueva E., Yalavarthi S., Berthier C.C., et al. Netting neutrophils induceendothelial damage, infiltrate tissues, and expose immunostimulatorymolecules in systemic lupus erythematosus // J. Immunol. 2011. № 187. R. 538-552.
19. Zhuang H., Han S., Xu Y. et al. Toll-like receptor 7-stimulated tumor necrosis factor alpha causes bone marrow damage in systemic lupus erythematosus // Arthritis & Rheumatology. 2014. № 66. R. 140-151.
20. Coquery C.M., Wade N.S., Loo W.M. et al. Neutrophils contribute to excess serum BAFF levels and promote CD4þ T cell and B cell responses in lupus prone mice // PLoS One. 2014. № 9. R. e102284.
21. Gateva V., Sandling J. K., Hom G. et al. A large-scale replication study identifies tnip1, prdm1, jazf1, uhrf1bp1 and il10 as risk loci for systemic lupus erythematosus // Nature Genetics. 2009. V. 41. № 11. R. 1228-1233.
22. Chong W.P., Ip W.K., Wong W.H.S., et al. Association of interleukin-10 promoter polymorphisms with systemiclupus erythematosus // Genes and Immunity. 2004. V. 5. № 6. R. 484-492.
23. López P., Gutiérrez C., Suáre A. IL-10 and TNFα Genotypes in SLE // Journal of Biomedicine and Biotechnology. 2010. Article ID 838390.
24. Eskdale J., Gallagher G., Verweij C.L., et al. Interleukin 10 secretion in relation to human il-10locus haplotypes // Proceedings of the National Academy of Sciences of theUnited States of America. 1998. V. 95. № 16. R. 9465-9470.
25. Li J., Pan H.F., Cen H. et al. Interleukin-21 as a potential therapeutictarget for systemic lupus erythematosus // Molecular Biology Reports. 2011. V. 38. № 6. R. 4077-4081.
26. Jacob C.O., Zhu J., Armstrong D.L. et al. Identification of irak1 as a riskgene with critical role in the pathogenesis of systemic lupus erythematosus // Proceedings of the National Academy of Sciences of the United States of America. 2009. V. 106. № 15. R. 6256-6261.
27. Graham R.R., Cotsapas C., Davies L., et al. Genetic variants near tnfaip3on 6q23 are associated with systemic lupus erythematosus // Nature Genetics. 2008. V. 40. № 9. R. 1059-1061.
28. Coppola N., Pisaturo M., Sagnelli C., et al. Role of genetic polymorphisms in hepatitis C virus chronic infection // World Journal of Clinical Cases. 2015. V. 3. № 9. R. 807-822.
29. Thompson A.J., et al. Interleukin-28 B polymorphism improves viralkinetics and is the strongest pretreatment predictor of sustained virologicresponse in genotype 1 hepatitis C virus // Gastroenterology. 2010. V. 139. № 1. R. 120-129.
30. Lin S.C., Kuo C.C., Tsao J.T., Lin L.J. Profiling the expression of interleukin(IL)-28 andIL-28 receptorα in system iclupusery thematosus patients // European Journal of ClinicalI nvestigation. 2012. V. 42. № 1. R. 61-69.
31. Egli A., Levin A., Santer D.M., et al. Immunomodulatory function of interleukin 28B during primary infection with cytomegalovirus // Journal of Infectious Diseases. 2014. V. 210. № 5. R. 717-727.
32. Krasnova T.N., Samokhodskaja L.M., Ivanickijj L.V. i dr. Vlijanie polimorfizma genov interlejjkina-10 iinterlejjkina-28 na razvitie i techenie volchanochnogo nefrita // Terapevticheskijj arkhiv. 2015. № 6. R. 40-44.
33. Ivanickijj L.V., Krasnova T.N., Samokhodskaja L.M. i dr. Vlijanie polimorfizmagenov vospalitelnykh citokinov na aktivnost i osobennosti klinicheskojj kartiny sistemnojj krasnojj volchanki // Klinicheskaja farmakologija i terapija. 2013. № 5. R. 24-29.
34. Borisov E.N., Krasnova T.N., Camokhodskaja L.M. i dr. Prognosticheskoe znachenie allelnykh variacijj genov, vlijajushhikh na sistemu gemostaza, v razvitii antifosfolipidnogo sindroma i porazhenija pochek u bolnykh sistemnojj krasnojj volchankojj // Terapevticheskijj arkhiv. 2014. № 6. R. 57-62.